The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 3, 2015, Pages 276-283

  Rizos, Christos V ^a   Kostapanos, Michael S ^a   Rizos, Evangelos C ^a   Tselepis, Alexandros D ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

impaired fasting glucose; low density lipoprotein cholesterol; low density lipoprotein cholesterol subfractions; prediabetes; rosuvastatin

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALYSIS; BLOOD; DIET RESTRICTION; DYSLIPIDEMIAS; MIDDLE AGED;

AGED; BLOOD GLUCOSE; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FASTING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROSUVASTATIN CALCIUM;

EID: 84928263977     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414549419     Document Type: Article

References (38)

1. Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. J Cardiovasc Dis. 2013 ; 1 (1). 1-2
2. Rizzo M, Barylski M, Rizvi AA, Montalto G, Mikhailidis DP, Banach M. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. Curr Pharm Des. 2013 ; 19 (21). 3858-3868
3. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006 ; 99 (1). 1-14
4. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res. 2012 ; 51 (4). 314-324
5. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982 ; 23 (1). 97-104
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19). 2486-2497
7. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011 ; 9 (5). 533-571
8. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010 ; 35 (2). 139-151
9. Ai M, Otokozawa S, Asztalos BF, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008 ; 101 (3). 315-318
10. Takagi H, Niwa M, Mizuno Y, Yamamoto H, Goto SN, Umemoto T. Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart Vessels. 2014 ; 29 (3). 287-299
11. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol. 2008 ; 590 (1-3). 327-332
12. Rizos CV, Liberopoulos EN, Tellis CC, Florentin M, Elisaf MS, Tselepis AD. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A(2). Metab Syndr Relat Disord. 2011 ; 9 (3). 217-223
13. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des. 2013 ; 19 (27). 4904-4912
14. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003 ; 26 (11). 3160-3167
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421
16. Tomaszewski M, Charchar FJ, Lacka B, et al. Epistatic interaction between beta2-adrenergic receptor and neuropeptide Y genes influences LDL-cholesterol in hypertension. Hypertension. 2004 ; 44 (5). 689-694
17. Uciechowski P, Oellig EM, Mariani E, Malavolta M, Mocchegiani E, Rink L. Effects of human Toll-like receptor 1 polymorphisms on ageing. Immun Ageing. 2013 ; 10 (1). 4
18. Kao WT, Yen YC, Lung FW. The effects of beta2 adrenergic receptor gene polymorphism in lipid profiles. Lipids Health Dis. 2008 ; 7: 20
19. Turtzo LC, Marx R, Lane MD. Cross-talk between sympathetic neurons and adipocytes in coculture. Proc Natl Acad Sci USA. 2001 ; 98 (22). 12385-12390
20. Arner P, Engfeldt P, Hellström L, et al. Beta-adrenoreceptor subtype expression in human liver. J Clin Endocrinol Metab. 1990 ; 71 (5). 1119-1126
21. Kaneto A, Miki E, Kosaka K. Effect of beta and beta2 adrenoreceptor stimulants infused intrapancreatically on glucagon and insulin secretion. Endocrinology. 1975 ; 97 (5). 1166-1173
22. Santulli G, Lombardi A, Sorriento D, et al. Age-related impairment in insulin release: the essential role of β(2)-adrenergic receptor. Diabetes. 2012 ; 61 (3). 692-701
23. Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids. 2013 ; 48 (6). 547-555
24. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998 ; 21 (3). 360-367
25. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 ; 22 (2). 233-240
26. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation. 2007 ; 116 (2). 151-157
27. Scharnagl H, Winkler K, Mantz S, Baumstark MW, Wieland H, Marz W. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2004 ; 112 (5). 269-277
28. Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care. 1999 ; 22 (11). 1771-1778
29. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999 ; 159 (22). 2661-2667
30. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003 ; 26 (10). 2713-2721
31. Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther. 2006 ; 20 (3). 205-217
32. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001 ; 47 (2). 266-274
33. Banuls C, Bellod L, Jover A, et al. Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type. Clin Chim Acta. 2012 ; 413 (1-2). 251-257
34. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis?. Curr Vasc Pharmacol. 2010 ; 8 (5). 612-631
35. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract. 2009 ; 63 (9). 1308-1313
36. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 ; 380 (9841). 565-571
37. Rizos CV, Milionis HJ, Kostapanos MS, et al. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther. 2010 ; 32 (3). 492-505
38. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 ; 129(25 suppl 2): S1-45